Receive monthly emails about the latest oncology research and technology, new patient services, resources and more!

Please select an option below to help us tailor your newsletter to best suit your content interests!

No thanks
LIVER CANCER: Unresectable: Child\\\'s A: First-Line: Immunotherapy: HIMALAYA

A Randomized, Open-label, Multi-center Phase III Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma

Title
AstraZeneca D419CC00002 (HIMALAYA HCC)
Study Title

A Randomized, Open-label, Multi-center Phase III Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma

Site Link
Malignancy
Liver cancer, Hepatocellular cancer: HCC
Stage
Disease Setting
Metastatic/Palliative
Line Of Therapy
1st Line
Investigational Agent
Tremelimumab, durvalumab
Drug Class
CTLA-4 inhibitor, PD-L1 inhibitor
PI
Brad Somer, MD
Sponsor
AstraZeneca
Phase
Status
Key Eligibility Criteria
Key Eligibility Criteria Details
  • Confirmed pathologic diagnosis of HCC (from tumor tissue)
  • Must not be eligible for locoregional therapy for unresectable HCC. Patients who progressed on local regional therapy are eligible if therapy was >28 days prior
  • Barcelona Clinic Liver Cancer (BCLC) stage B or stage C
  • Child-Pugh Score class A
  • ECOG PS 0-1
  • HBV or HCV may be allowed depending on activity (may not have both together)
  • Measurable disease
  • No prior receipt of durvalumab, tremelimumab, or sorafenib
  • No prior receipt of any PD-1, PD-L1, or CTLA-4 antibody
  • No autoimmune disease within the last 5 years
  • No CNS mets
  • No fibrolamellar or sarcomatoid HCC or mixed cholagiocarcinoma with HCC
  • No recent steroid use (>10 mg prednisone/day)
Objective

Primary- OS:  Secondary- TTP, PFS, ORR, DCR, DoR, PK, QoL

Assessment Frequency
_
Assessment Frequency 2
_



Assessment Frequency Link
Path
Hepatocellular carcinoma
Dosing Frequency
Control Agents
sorafenib
Study Protocol
Randomized
Yes
X